Human Genome's Poison Pill Survives As GSK Eyes Coup

Biotech company Human Genome Sciences Inc. beat a legal challenge to the poison pill it is using to fend off a $2.6 billion hostile takeover by GlaxoSmithKline PLC on Thursday, even...

Already a subscriber? Click here to view full article